Voriconazole use for endemic fungal infections

Alison Gail Freifeld, Laurie Proia, David Andes, Larry M. Baddour, Janis Blair, Brad Spellberg, Sandra Arnold, Arnold Lentnek, L. Joseph Wheat

Research output: Contribution to journalArticle

86 Scopus citations


In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.

Original languageEnglish (US)
Pages (from-to)1648-1651
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number4
Publication statusPublished - Apr 1 2009


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Freifeld, A. G., Proia, L., Andes, D., Baddour, L. M., Blair, J., Spellberg, B., ... Wheat, L. J. (2009). Voriconazole use for endemic fungal infections. Antimicrobial Agents and Chemotherapy, 53(4), 1648-1651. https://doi.org/10.1128/AAC.01148-07